Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs | Zendy

B. V. Nikonenko | Zendy; Marina Protopopova | Zendy; Rowena Samala | Zendy; Leo Einck | Zendy; Carol A. Nacy | Zendy

Open Access

Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs

Author(s) -

B. V. Nikonenko,

Marina Protopopova,

Rowena Samala,

Leo Einck,

Carol A. Nacy

Publication year - 2007

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01326-06

Subject(s) - pyrazinamide , ethambutol , isoniazid , medicine , tuberculosis , antibiotics , drug , rifampicin , pharmacology , antibacterial agent , pharmacotherapy , microbiology and biotechnology , pathology , biology

Substitution of the new diamine antibiotic SQ109 for ethambutol in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs rifampin and isoniazid, with or without pyrazinamide: at 8 weeks, lung bacteria were 1.5 log10 lower in SQ109-containing regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research